NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
73 trialsNCT03600155 2026-02-17
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03245892 2025-12-17
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04850755 2025-09-25
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
National University Hospital, Singapore
Phase 1 Completed
NCT05444530 2025-07-20
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Completed
NCT03508570 2025-05-22
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01703507 2025-05-16
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Thomas Jefferson University
Phase 1 Completed
NCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04463368 2025-03-28
SCANDIUM II
Vastra Gotaland Region
Phase 1 Completed
NCT03956680 2025-02-19
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1 Completed
NCT04121676 2025-01-13
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
Agenus Inc.
Phase 1 Completed
NCT04855929 2024-11-08
ANV419-001
Anaveon AG
Phase 1 Completed
NCT05169957 2024-11-05
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT03523819 2024-09-19
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT03752398 2024-07-05
DUET-3
Xencor, Inc.
Phase 1 Completed
NCT03829111 2024-07-03
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
City of Hope Medical Center
Phase 1 Completed
NCT04518046 2024-06-05
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Mirati Therapeutics Inc.
Phase 1 Completed
NCT01621490 2024-04-23
PD-1
Bristol-Myers Squibb
Phase 1 Completed
NCT03798639 2024-04-12
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03373188 2024-03-20
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Emory University
Phase 1 Completed
NCT03728179 2024-02-20
RACIN
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT02467361 2023-11-14
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04721301 2023-10-17
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
University Hospital Heidelberg
Phase 1 Completed
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01935921 2023-06-15
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00790010 2023-05-11
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT04084951 2023-04-14
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Completed
NCT03305445 2023-02-15
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02032810 2023-01-20
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02829931 2023-01-19
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02307149 2023-01-17
MITCI
Viralytics
Phase 1 Completed
NCT02311920 2023-01-10
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT04132817 2022-12-02
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed
NCT03532217 2022-08-05
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Washington University School of Medicine
Phase 1 Completed
NCT02977156 2022-07-25
ISI-JX
Centre Leon Berard
Phase 1 Completed
NCT03525795 2022-05-18
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
Constellation Pharmaceuticals
Phase 1 Completed
NCT03203876 2022-03-10
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02381314 2022-02-08
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
MacroGenics
Phase 1 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01454102 2021-10-12
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
Phase 1 Completed
NCT01822509 2021-06-24
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
Phase 1 Completed
NCT01024231 2021-03-22
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Bristol-Myers Squibb
Phase 1 Completed
NCT00064129 2020-07-30
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT02174172 2020-05-12
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02516527 2020-05-01
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT01473940 2020-03-06
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Northwestern University
Phase 1 Completed
NCT00836407 2020-02-24
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT04274816 2020-02-18
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
Amsterdam UMC, location VUmc
Phase 1 Completed